Supriya Lifescience Ltd

Supriya Lifescience Ltd Performance

₹173.15
Day's Price Range
₹189.35
₹170.15
52-Week Price Range
₹516
1 Month Return-7.68 %
3 Month Return-21.58 %
1 Year Return-61.14 %

Analyst Rating

based on 1 analysts

BUY
100.00%
Buy
0.00%
Hold
0.00%
Sell

Based on 1 analysts offering long term price targets for Supriya Lifescience Ltd. An average target of ₹278

Source: S&P Global Market Intelligence

Supriya Lifescience Ltd Price Movements

  • Supriya Lifescience fell 4% on 28 Mar, 2023

    Supriya Lifescience declined amid reports of Dovetail India Fund selling 5.47 lakh shares (0.68%) at Rs 177.08 per share capped the gains.

Insights on Supriya Lifescience Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Retail Holding Up
    img

    Retail Investor have increased holdings from 16.09% to 17.63% in Dec 2022 quarter

  • imgNO EFFECT

    Promoter Holding Unchanged
    img

    Promoters holdings remained unchanged at 68.24% of holdings in Dec 2022 quarter

  • imgNO EFFECT

    Against Peers
    img

    In the last 1 year, Sun Pharmaceuticals Industries Ltd has given 8.6% return, outperforming this stock by 69.7%

  • imgNEGATIVE IMPACT

    FII Holding Down
    img

    Foreign Institutions have decreased holdings from 6.79% to 6.24% in Dec 2022 quarter

  • imgNEGATIVE IMPACT

    Price Dip
    img

    In the last 6 months, SUPRIYA stock has moved down by -38.3%

Supriya Lifescience Ltd Shareholding Pattern

InvestorsHoldings %Prev. 4 periods3M change
Promoter Holdings
68.24%
0.00
Foreign Institutions
6.24%
-8.06
Mutual Funds
2.38%
0.00
Retail Investors
17.63%
9.55
Others
5.51%
-15.20

Supriya Lifescience Ltd Company Information

The company was incorporated as Supriya Lifescience Limited on 26 March 2008 upon the conversion of M/s Supriya Chemicalsa partnership firm into a public limited company.The company commenced operations on 01 April 2008.The company is engaged in manufacturing and export of active pharmaceutical ingredientsAPIs.The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredientswith a focus on research and development. As of 31 March 2021the company have niche product offerings of 39 APIs focused on diverse therapeutic segments such as antihistamine analgesic anaesthetic vitamin antiasthmatic and antiallergic.The company have consistently been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India contributing to 4555 and 6570 respectivelyof the API exports from India between Fiscal 2017 and 2020.The company is among the largest exporters of Salbutamol Sulphate from India in Fiscal 2020 in terms of volume.The companys products are approved by various international regulatory authorities such as USFDA EUGMP EDQM SFDA NMPA ANVISA KFDA PMDA TGA and Taiwan FDA. As of 31 March 2021 the company have filed 11 active DMFs with USFDA and seven active CEPs with EDQM for API products in therapeutic areas such as antihistamine analgesic anaesthetic vitamin antiasthmatic and antiallergic.The companys business operations are supported by a modern manufacturing facility located in Parshuram Lote Maharashtra. The manufacturing facility is spread across 23806 sq.mts having reactor capacity of 332 KL per day.The company presently operate five cleanrooms and are setting up two new clean rooms that are expected to be commercialised in the first quarter of Fiscal 2022. The new clean rooms will add manufacturing capacity of 215 KL per day.On 31 March 2012the company has issued and allotted 3002400 equity shares of Rs 10 each as bonus shares to the shareholders in the ratio of 12:1.On 31 March 2013the company has issued and allotted 1626302 equity shares of Rs 10 each as bonus shares to the shareholders in the ratio of 1:2.On 01 October 2015the company has issued and allotted 9757804 equity shares of Rs 10 each as bonus shares to the shareholders in the ratio of 2:1On 26 December 2020the company has subdivided its face value of equity shares from Rs 10 each to Rs 2 each.During the month of December 2021the company came out with an Rs 700crore public issue which comprised of a fresh issue of Rs 200 crore and an offer for saleOFS of Rs 500 crore by the promoter Satish Waman Wagh.The IPO shares were allotted at the price of Rs 274 per share including a premium of Rs 272 per share.The allotted shares were listed on the BSE Ltd and National Stock Exchange of India LtdNSE on 28 December 2021.

Supriya Lifescience Ltd Share Price: ₹175.95 per share as on 28 Mar, 2023 04:01 PM
Supriya Lifescience Ltd Market Capitalisation: ₹1,594.36Cr as of today
Supriya Lifescience Ltd Listing date: 12 Dec, 1995
Supriya Lifescience Ltd Chairperson Name: Satish Waman Wagh
OrganisationSupriya Lifescience Ltd
HeadquartersMumbai
IndustryPharmaceuticals
E-voting on sharesClick here to vote

Frequently Asked Questions

Supriya Lifescience Ltd(SUPRIYA) share price today is ₹175.95 (last updated 28 Mar, 2023 at 04:01 PM)

  • Today’s highest price of Supriya Lifescience Ltd(SUPRIYA) is ₹189.35.
  • Today’s lowest price of Supriya Lifescience Ltd(SUPRIYA) is ₹173.15.
  • (last updated 28 Mar, 2023 at 04:01 PM)
Today’s traded volume of Supriya Lifescience Ltd(SUPRIYA) is 304232.
Today’s market capitalisation of Supriya Lifescience Ltd(SUPRIYA) is ₹1,594.36Cr.
Supriya Lifescience Ltd(SUPRIYA)Price
52 Week High₹516.00
52 Week Low₹170.15
  • (last updated 28 Mar, 2023 at 04:01 PM)
  • Supriya Lifescience Ltd(SUPRIYA) share price is ₹175.95 (last updated 28 Mar, 2023 at 04:01 PM). It is down -65.90% from its 52 Week High price of ₹516.00
    Supriya Lifescience Ltd(SUPRIYA) share price is ₹175.95 (last updated 28 Mar, 2023 at 04:01 PM). It is up 3.41% from its 52 Week Low price of ₹170.15
    Supriya Lifescience Ltd(SUPRIYA)Returns (%)
    1 Day Returns-3.72%
    1 Month Returns-7.68%
    1 Year Returns-61.14%
    3 Year Returns-53.24%
    5 Year Returns-53.24%
    Supriya Lifescience Ltd(SUPRIYA) share price is ₹175.95 and its price to earning (PE) is 0.00. A high PE ratio indicates that a share price is overvalued, or investors are expecting a high growth rate in the future.